Guanylin and uroguanylin are small peptides containing two disulfide bonds that activate membrane guanylate cyclase-receptors in the intestine, kidney and other epithelia. Hybridization assays with a uroguanylin complementary DNA (cDNA) detected uroguanylinlike messenger RNAs (mRNAs) in the opossum spleen and testis, but these transcripts are larger than uroguanylin mRNAs. RT of RNA from spleen to produce cDNAs for amplification in the PCR followed by cloning and sequencing revealed a novel lymphoid-derived cDNA containing an open reading frame encoding a 109-amino acid polypeptide. This protein shares 84% and 40% of its residues with preprouroguanylin and preproguanylin, respectively. A 15-amino acid, uroguanylin-like peptide occurs at the COOH-terminus of the precursor polypeptide. However, this peptide is unique in having only three cysteine residues. We named the gene and its peptide product lymphoguanylin because the source of the first cDNA isolated was spleen and its mRNA is expressed in all of the lymphoid tissues tested. A 15-amino acid form of lymphoguanylin containing a single disulfide bond was synthesized that activates the guanylate cyclase receptors of human T84 intestinal and opossum kidney (OK) cells, although with less potency than uroguanylin and guanylin. Northern and/or RT-PCR assays detected lymphoguanylin mRNA transcripts in many tissues and organs of opossums, including those within the lymphoid/ immune, cardiovascular/renal, reproductive, and central nervous organ systems. Lymphoguanylin joins guanylin and uroguanylin in a growing family of peptide agonists that activate transmembrane guanylate cyclase receptors, thus influencing target cell function via the intracellular second messenger, cGMP. (Endocrinology 140: 1800 -1806, 1999) 
G UANYLIN and uroguanylin are small peptides containing four conserved cysteines that were initially isolated from rat intestine and opossum urine, respectively (1, 2) . These peptides activate transmembrane guanylate cyclase (GC) signaling molecules located on the apical surfaces of cells in the intestine, kidney, and other epithelia (3) (4) (5) . GC receptors for guanylin and uroguanylin are also targets for the heat-stable enterotoxins (ST) secreted by enteric bacteria that cause traveler's diarrhea (6, 7) . ST peptides act as molecular mimics of the endogenous mammalian peptides. Isolation of complementary DNAs (cDNAs) encoding preproguanylin and preprouroguanylin revealed that the bioactive peptides are located at the COOH-termini of larger precursors containing 100 -116 residues (8 -13) . Expression of messenger RNA (mRNA) transcripts encoding guanylin or uroguanylin is greatest in the intestinal mucosa (8, 9, (12) (13) (14) (15) . However, mRNAs for both peptides have been detected in several different tissues in the opossum and rat (12, 13, 15, 16) . Uroguanylin and guanylin stimulate the enzymatic activities of GC receptors in the gastrointestinal epithelium and kidney (1, 2, 5, 14) . In the intestine, guanylin and uroguanylin markedly increase the transepithelial secretion of chloride and bicarbonate anions (1, 2, 17, 18) . Activation of receptors by these peptides in the kidney elicits natriuresis, kaliuresis, and diuresis (19, 20) .
Recent studies revealed that mRNA transcripts encoding guanylin and/or uroguanylin and their GC receptors are expressed in many tissues of the opossum (12, 16) . A novel mRNA transcript that hybridizes with both uroguanylin and guanylin cDNA probes and is longer than either the 1.2-kb uroguanylin or the 0.8-kb guanylin mRNA was detected by Northern assays using RNA isolated from spleen and testes of the North American opossum, Didelphis virginiana. Herein, we provide new information for cDNA and deduced protein structures, the biological activity, and mRNA expression of a unique member of the guanylin peptide family. The gene and its protein product were named lymphoguanylin because the first cDNA isolated was derived from spleen mRNA, and the active peptide domain is similar in primary structure to uroguanylin and guanylin.
Materials and Methods Animals
Opossums were obtained under a permit from the Missouri Department of Conservation to W.J.K. Animals were housed in the laboratory animal medicine facility of the School of Medicine and used under approved protocols (5) . blood cells, bone marrow, kidney, opossum kidney (OK) cells, heart, ovary, cerebellum, and testis and used as templates for the PCR. Total RNA was extracted using the RNeasy kit (Qiagen, Chatsworth, CA). Oligo(deoxythymidine) 18 -primed cDNAs were synthesized from 3 g total RNA using reverse transcriptase (Superscript II, Life Technologies, Gaithersburg, MD). The first set of PCR primers used for PCR amplification of uroguanylin-like cDNAs corresponded to nucleotides Ϫ21 to Ϫ2 (5Ј-GGAACAAGACTGGCAGACAC-3Ј) and nucleotides 266 -247 (5Ј-GCTCTGAAGATGTTGGCAGC-3Ј) of the opossum preprouroguanylin cDNAs isolated from a colon cDNA library (12) . These primers amplified cDNA products of 287 bp that lacked the region containing the COOH-terminal active peptide (16) . A second set of primers consisting of 5Ј-GGAACAAGACTGGCAGACAC-3Ј and 5Ј-GTGGGGGCACA-GAGTGAGGT-3Ј was derived from nucleotides Ϫ21 to Ϫ2 and nucleotides 402 to 383 within the 3Ј-and 5Ј-untranslated domains, respectively, of opossum preprouroguanylin cDNA (12, 16) . The first primer set generated a partial cDNA identical to a corresponding domain within the cDNAs produced by PCR using the second set of primers. The second pair of oligonucleotide primers generated identical 385-bp cDNA products (excluding primers) when spleen, thymus, lymph nodes, circulating white blood cell, bone marrow, kidney, OK cells, heart, ovary, cerebellum, and testis cDNAs were used as templates and 30 cycles of the PCR were carried out at 93 C for 1 min, at 56.5 C for 1 min, and at 72 C for 1.5 min using Taq DNA polymerase (U.S. Biochemical Corp., Cleveland, OH). The PCR-generated cDNA products were ligated into the plasmid vector pCR2.1 (TA cloning kit, Invitrogen, San Diego, CA), and molecular cDNA clones were isolated and sequenced. Automated sequencing was performed by the DNA Core Laboratory of the Missouri University Molecular Biology Program (Columbia, MO). Independent PCR-generated cDNA clones derived from the spleen and other tissues of as many as eight different animals were sequenced.
Northern assays
Total RNA (20 -40 g) was subjected to electrophoresis in formaldehyde-agarose gels and then transferred to nylon membranes (ZetaProbe, Bio-Rad Laboratories, Inc., Hercules, CA). The blots were hybridized with either the spleen-derived cDNA or the uroguanylin cDNA and a ␤-actin cDNA as previously described (12, 16) . Prehybridization was performed for 2 h with QuickHyb (Stratagene, La Jolla, CA) at 69 C, followed by hybridization for 4 h at 65 C with each cDNA probe labeled by random priming (Boehringer Mannheim, Indianapolis, IN). The blots were washed twice with 2 ϫ SSC (standard saline citrate)-0.1% SDS for 5 min at room temperature. Exposure to x-ray film was performed at Ϫ80 C with intensifying screens.
Synthesis of peptides
Opossum lymphoguanylin (QEECELCINMACTGY), opossum uroguanylin (QEDCELCINVACTGC), and opossum guanylin (SHTCEI-CAYAACAGC) were synthesized by the solid phase method on an PE Applied Biosystems model 431A peptide synthesizer (Foster City, CA) and purified by reverse phase C 18 chromatography as described previously (1, 2).
Cell culture
T84 cells were cultured in DMEM and Ham's F-12 medium (1:1) supplemented with 5% FBS, 60 mg penicillin, and 100 mg streptomycin/ml as previously described (2) . Opossum kidney (OK-E) cells were cultured in DMEM and Ham's F-12 medium (1:1) with 5% FBS as previously described (5) .
cGMP accumulation bioassay
T84 or OK-E cells were cultured in 24-well plastic dishes, and cGMP levels were measured in control and agonist-stimulated cells by RIA (2, 5) . Synthetic peptides were dissolved in 200 l DMEM containing 20 mm HEPES and 1 mm isobutylmethylxanthine at pH 7.4. Cells were washed twice with DMEM before the addition of 200 l DMEM containing the agonist peptides or vehicle to T84 or OK-E cells followed by incubation at 37 C for 40 min. After incubation, the reaction medium was aspirated, cells were washed with PBS, and 0.2 ml 3.3% perchloric acid was added per well to extract cGMP. The extract was neutralized and used to measure cGMP by RIA (2, 5) .
Results
When total RNA preparations from opossum duodenum, spleen, cerebellum, and testis were subjected to Northern assays using a uroguanylin cDNA, we detected an expected uroguanylin mRNA of 1.2 kb (12) in the duodenum (Fig. 1) . However, the transcripts in spleen and testis that hybridize with this uroguanylin cDNA are larger than the intestinal transcript. These larger mRNAs also hybridized with a guanylin cDNA probe (data not shown). Then, RNA was isolated from spleen to make cDNAs, and oligonucleotide primers were prepared that anneal to uroguanylin cDNAs for amplification by the PCR of a 287-bp cDNA product (16) . This cDNA was cloned, and nucleotide sequence analyses revealed that the spleen cDNA was related to uroguanylin and guanylin cDNAs, but this mRNA in the spleen was clearly derived from a novel guanylin-like gene. Because this spleen cDNA did not contain the COOH-terminus of the precursor polypeptide, which encodes the bioactive peptide domain, a different 3Ј-primer was prepared for PCR cloning (12, 16) . This primer anneals to a region of the 3Ј-untranslated domain distal to the stop codon in the uroguanylin cDNAs. The 5Ј-primer used in all subsequent PCR-based cloning experiments anneals within the 5Ј-untranslated region flanking the initiation codon of the open reading frame of uroguanylin cDNAs (12, 16) . Using spleen-derived cDNA templates and these primers, a 385-bp cDNA was amplified by PCR and isolated by molecular cloning ( Fig. 2A) . Sequence analyses of multiple independent cDNA clones from several different animals revealed that this cDNA is 92.7% identical to the corresponding nucleotide sequences for preprouroguanylin reported previously (12) . The nucleotide and deduced amino acid sequences of the protein demonstrate that the uroguanylin/guanylin-like mRNA transcripts in spleen are derived from a new gene in the guanylin family. The open reading frame within the spleen-derived cDNA encodes a 109-amino acid polypeptide that is 84% identical to preprouroguanylin and 40% identical to preproguanylin. The gene and its protein product were named lymphoguanylin because the cDNA was isolated from spleen mRNA/cDNA and the polypeptide belongs to the guanylin peptide family.
At the COOH-terminus of preprolymphoguanylin is a 15-
Hybridization analysis of uroguanylin-like mRNA transcripts in opossum tissues. An opossum uroguanylin cDNA hybridizes with the 1.2-kb uroguanylin mRNAs (left arrow) in the duodenum, but larger mRNA transcripts also hybridize with this cDNA in RNA isolated from spleen and testis (right arrow). The actin mRNA is also depicted in this Northern assay.
amino acid peptide that is 80% identical to uroguanylin but shares only 40% identity with guanylin (Fig. 2B) . Illustrated for comparison are the primary structures of the opossum forms of lymphoguanylin, uroguanylin, guanylin, and an Escherichia coli ST peptide. A major difference within the structure of lymphoguanylin is the tyrosine 109 residue found at the COOH-terminus of this peptide. All of the guanylin and uroguanylin peptides identified to date have a cysteine at this position (1, 2, 8 -13, 21, 22) . The disulfide bonds formed between the first and third cysteines and linking the second to fourth cysteines in the peptide chain are considered to be required for optimal biological activity in the guanylin and uroguanylin peptides (1, 2). The replacement of cysteine 109 with the tyrosine 109 residue represents a unique molecular structure within the guanylin family of bioactive peptides (1, 2) . Lymphoguanylin is uroguanylinlike because it has two glutamate residues in the NH 2 -terminal domain of this peptide. Opossum uroguanylin has glutamate and aspartate residues, and all other uroguanylin molecules in mammalian species have acidic residues at these positions (11) (12) (13) (14) (15) 21) . Shared between lymphoguanylin and uroguanylin is an internal asparagine residue, which is also found in the bacterial ST peptides (2, 21) . Guanylin peptides have an aromatic amino acid at this position, which makes guanylin sensitive to hydrolysis and inactivation by chymotrypsin (23, 24) . The third difference is the methionine 104 substitution in lymphoguanylin for the valine 104 of uroguanylin. The 23-residue signal peptide of preprouroguanylin is 87% identical to a corresponding peptide domain at the NH 2 -terminus of preprolymphoguanylin (24) . Near the NH 2 -termini of opossum prolymphoguanylin, prouroguanylin, and proguanylin polypeptides are highly conserved domains consisting of the peptide sequence L(D/E)SVKKL (12, 16) . A biological function for this portion of the prohormones has not yet been elucidated. A lymphoguanylin peptide (Q 95 EECELCINMACTGY 109 ) was synthesized and then oxidized to form a disulfide bond between cysteine 98 and cysteine 106. The cysteine 100 residue was protected so that a single intramolecular disulfide would result from oxidation of this peptide. The crude peptide was active in the T84 cell cGMP accumulation bioassay; thus, we partially purified the synthetic lymphoguanylin by reverse phase HPLC (RP-HPLC) using this bioassay to detect the active peptide. Bioactive lymphoguanylin eluted at approximately 25% acetonitrile, whereas uroguanylin and guanylin eluted at about 20 -21% acetonitrile under these RP-HPLC conditions (Fig. 3A) . About 360 g active lymphoguanylin were isolated from about 3 mg peptide. The RP-HPLC-purified lymphoguanylin stimulates cGMP production in human T84 intestinal cells, but its apparent potency is less than that of either uroguanylin or guanylin (Fig.  3B ). Concentration-response curves for these peptide agonists suggest that all three peptides are full agonists in the stimulation of the intestinal form of GC receptors expressed in T84 cells (1, 2) . Although lymphoguanylin was less potent than either uroguanylin or guanylin, this novel peptide stimulated cGMP accumulation in T84 cells greater than 300-fold. When the potencies of these peptides were examined in an OK cell line, we observed that GC receptors in kidney cells were also activated by lymphoguanylin (Fig. 3C) . The rank order of peptide agonist potencies remained similar (uroguanylin Ͼ guanylin Ͼ lymphoguanylin), but 100 m lymphoguanylin stimulated cGMP accumulation by only about 5-fold over the basal level in kidney cells. In contrast, 10 m uroguanylin increased cGMP by 206-fold, and 10 m guanylin increased cGMP by 88-fold over the basal level in OK cells.
Northern assays detected mRNA transcripts of approximately 1.2 and 1.6 kb in total RNA preparations isolated from opossum tissues when a lymphoguanylin cDNA was used as a probe (Fig. 4A) . Tissues with the most abundant lymphoguanylin mRNAs of about 1.6 kb are atria and ventricles of heart and kidney cortex. The lymphoguanylin cDNA also hybridizes with an approximately 1.2-kb uroguanylin mRNA in mucosae from the duodenum, jejunum, and ileum of small intestine and the cecum and colon of large intestine and in esophagus (Fig. 4B) . We have also detected about 1.6-kb mRNAs for lymphoguanylin using Northern assays in RNA from spleen, thymus, and testis ( Fig. 1 and data not  shown) . When total RNA from either lymphoid tissues or brain were tested in Northern assays, we often observed that lymphoguanylin mRNAs are either undetectable or margin- ally detectable using this relatively insensitive method. Spleen appears to have the most abundant levels of lymphoguanylin mRNA within tissues of the lymphoid/immune system when examined by Northern assays (data not shown). Because of the lower expression levels of lymphoguanylin mRNA transcripts in these tissues, RT-PCR was used to amplify the mRNA-cDNAs prepared from spleen, thymus, lymph nodes, circulating white blood cells, bone marrow, cerebellum, and testis. Lymphoguanylin cDNAs of the anticipated size were detected by ethidium bromide and confirmed by Southern blots using a [ 32 P]lymphoguanylin cDNA (Fig. 4C) . These cDNAs were then isolated by molecular cloning, and nucleotide sequence analyses revealed that the cDNA clones derived from RNA in the thymus, lymph nodes, circulating white blood cells, bone marrow, spleen, cerebellum, kidney, OK cells, testis, ovary, and heart are identical to the 385-bp lymphoguanylin cDNAs that were first isolated from the spleen and shown in Fig. 2A . In addition to these lymphoguanylin cDNAs, we also isolated and sequenced uroguanylin cDNA clones when RNA from the kidney and heart was reverse transcribed and used as template in the PCR (data not shown).
Discussion
A third guanylin-like peptide has been sought since uroguanylin was isolated from opossum urine (2) . This inquiry culminated by isolating cDNAs encoding preprolymphoguanylin, a third and unique member of the guanylin regulatory peptides (1, 2) . The cDNAs encoding lymphoguanylin were isolated from several lymphoid tissues and white blood cells, as well as heart, testis, ovary, kidney, OK cells, and cerebellum. Preprolymphoguanylin is 84% identical to preprouroguanylin (12) . Precursors of lymphoguanylin and uroguanylin share only 40% identity with preproguanylin (16) . Lymphoguanylin has a distinct structural difference because it contains only one intramolecular disulfide (1, 2) . Synthetic lymphoguanylin with a disulfide bond between cysteine 98 and cysteine 106 activates GC receptors on human T84 intestinal cells acting as a full agonist. This disulfide pairing was chosen because these cysteines in guanylin and uroguanylin form an intramolecular disulfide (1, 2). Other possible disulfide isomers of guanylin appear to be inactive or have markedly reduced potency (25) . Lymphoguanylin containing a single disulfide elicited greater than 300-fold increases in intracellular cGMP, but this peptide was less potent than either synthetic uroguanylin or guanylin in the intestinal bioassay. Lymphoguanylin may also have reduced efficacy for activation of a renal GC receptor in OK cells (5) . It is possible that lymphoguanylin may exhibit selectivity for activation of intestinal GC receptors compared with activation of renal receptors (5, 16) . This interpretation is complicated because we used a heterologous bioassay with human intestinal GC receptors to test the biological activity of opossum peptides. Interpretation of results from the OK cell cGMP bioassay is simplified because this assay uses opossum lymphoguanylin, uroguanylin, and guanylin and kidney cells derived from opossums. It may be postulated that another receptor for lymphoguanylin occurs in the kidney and/or myocardium, tissues that express high levels of lymphoguanylin mRNA (5) .
E. coli ST peptides have six cysteines and three intramolecular disulfide bonds that are important determinants of biological potency (26) . These disulfide pairings in STs provide a peptide conformation with the greatest potency. Isolation of guanylin and uroguanylin containing four cysteines and two disulfides identified ST-like endogenous mammalian peptides (1, 2) . Two disulfides in guanylin and uroguanylin produce molecular conformations that elicit optimal bioactivity (1, 2, 25) . Thus, it was surprising to find that synthetic lymphoguanylin containing a single disulfide also activates intestinal and renal GC receptors. The molecular conformation elicited by a single disulfide may contribute to the reduced potency of lymphoguanylin. However, this form of lymphoguanylin may not accurately reflect the bioactive lymphoguanylin in vivo because this peptide was identified by cDNA cloning, whereas guanylin and uroguanylin were isolated as bioactive peptides from intestinal mucosa and urine (1, 2) .
In the intestine, uroguanylin and guanylin stimulate chloride and bicarbonate secretion via local release of these enteric peptides into the intestinal lumen (1, 2, 17, 18) . Through this paracrine mechanism, guanylin and uroguanylin regulate intestinal fluid secretion and also neutralize strong acids within the intestinal lumen by controlling bicarbonate secretion during digestion. Another physiological role for uroguanylin occurs in an endocrine link between the intestine and kidney via circulating uroguanylin and prouroguanylin to regulate urinary NaCl excretion (12, 27) . A natriuretic factor such as uroguanylin was predicted to exist in the digestive system as a mechanism to regulate salt balance (28) . Consistent with this endocrine axis is the finding that high salt diets stimulate uroguanylin and sodium excretion in the urine (29) . Plasma uroguanylin is delivered in the glomerular filtrate to GC receptors located on apical surfaces of renal tubular cells (5, 30) . Uroguanylin, guanylin, or E. coli ST are potent natriuretic, kaliuretic, and diuretic peptides in both the perfused rat kidney and in mice in vivo, indicating that renal tubular GC receptors are accessible to circulating peptides (19, 20, 31 ). An intrarenal paracrine mechanism for uroguanylin may also exist, because uroguanylin mRNAs are expressed in the kidney (8, 13, 22) . A different physiological role for lymphoguanylin in the kidney is implied because of the high renal mRNA expression of lymphoguanylin coupled with a relatively low potency and efficacy of this peptide as an agonist at renal GC receptors. Accordingly, a novel receptor for lymphoguanylin could be present in the kidney and/or other tissues that produce lymphoguanylin mRNA transcripts.
A communication pathway for lymphoguanylin may also exist between cells within the lymphoid/immune system. It was previously reported that a rat basophilic leukemia cell responds to E. coli ST with increases in cGMP and histamine release (32, 33) . Moreover, administration of E. coli ST to mice modulates the immune response to treatment with sheep red blood cells (34) . In recent studies, we isolated a cDNA that encodes the catalytic domain of a GC receptor for guanylin peptides, and the mRNA encoding this GC receptor is expressed in lymphoid as well as other tissues (16) . This GC receptor in cells within the lymphoid/immune system may serve as a target for regulation of intracellular cGMP by either lymphoguanylin or other guanylin peptides that are produced locally in lymphoid tissues.
Isolation by molecular cloning of lymphoguanylin cDNAs from mRNA transcripts expressed in tissues within the lymphoid/immune, cardiovascular/renal, reproductive, and central nervous organ systems reveals that three different genes encode lymphoguanylin, guanylin, and uroguanylin (2, 12, 16) . It is possible that a homologous lymphoguanylin gene is present in the genomes of all mammals. On the other hand, the lymphoguanylin gene could be unique to Marsupialia (metatherian mammals) and may not have evolved in Eutheria (placental mammals). Guanylin and uroguanylin genes were derived from a common ancestral gene early in mammalian evolution because both genes are present in eutherian and metatherian mammals (1, 2, 8 -16 ). Guanylin and uroguanylin genes are located close together on mouse chromosome 4 and human chromosome 1, suggesting their formation by gene duplication (35, 36) . The primary structure of opossum preproguanylin shares only 40% identity with preprouroguanylin (12, 16) . Preprouroguanylin and preprolymphoguanylin are 92.7% and 84% identical at nucleotide and amino acid sequence levels, respectively, which is consistent with a more recent gene duplication event.
Whether the lymphoguanylin gene was present in mammalian ancestors of extant marsupial and placental mammals is an important question. Vertebrate ancestors of Eutheria and Marsupialia lived more than 130 million yr ago; thus, the lymphoguanylin gene could have arisen after the evolutionary divergence of placental and marsupial mammals (37) . However, a long form of an uroguanylin-like mRNA transcript found in the testis of rats is an intriguing candidate mRNA encoding a putative eutherian homolog of lymphoguanylin (13).
In conclusion, three different guanylin regulatory peptides together with their GC receptors provide a novel signal transduction pathway for cGMP-mediated regulation of cellular function. Discovery of lymphoguanylin coupled with recent evidence that additional subtypes of membrane GC receptors occur in the intestine suggest that signaling mechanisms for guanylin peptides is complex (14, 16, 38) . Novel biological actions of these peptides are emerging with the demonstration that uroguanylin modulates pulmonary function in guinea pigs and that human airway cells have guanylinregulated chloride conductances (39, 40) . Identification of lymphoguanylin offers the intriguing possibility of finding a fourth guanylin-like gene and bioactive peptide in opossums. Uroguanylin and lymphoguanylin were both identified in experiments with opossums (2, 5) . It is likely that additional insights into the cell and molecular biology of guanylin regulatory peptides will be provided using this novel experimental animal.
